A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.
about
CRISPR/Cas9: at the cutting edge of hepatology.Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.CRISPR system for genome engineering: the application for autophagy study.Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier.CRISPR/Cas9: A Potential Life-Saving Tool. What's next?CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects.Engineering the Delivery System for CRISPR-Based Genome Editing.CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy.In vivo genome editing thrives with diversified CRISPR technologies.Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell Type Specific Gene Editing.Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles.DMSO increases efficiency of genome editing at two non-coding loci.Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs.Tools for translation: non-viral materials for therapeutic mRNA deliveryHigh-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editingTransfection by cationic gemini lipids and surfactantsNovel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future ChallengesCRISPR-delivery particles targeting nuclear receptor-interacting protein 1 () in adipose cells to enhance energy expenditure
P2860
Q39294371-435937A3-341D-4999-8D17-FFC64C2F314DQ39319380-AD75F0C7-328E-48CA-9B65-15075C2E3715Q41919375-0EE11845-6FF2-4EA5-A891-C93C531ADE86Q42342646-31865FC3-36B6-454C-8017-0671415867E0Q45875380-C742FB6F-00C5-4DA1-B820-BF8433D03B1FQ47095305-80300A5F-A440-4E89-8791-78B1DCB41FEEQ47161696-B9A63CD7-73D5-41AA-8015-DA80575E77C8Q47198006-937DA4F1-6CDA-45EE-8690-47C2B4C50D3EQ47553089-5075275E-2701-4251-A253-626DC723F82FQ48556291-8D91BE98-AB90-483D-B849-BDB6739D32AEQ52363995-5EC80318-6576-4FB1-835F-B78AB066B9CDQ52429666-9A7C0B49-FAC4-4D35-BAE1-446F83E43AF2Q52431500-4CEA36BA-90E4-4156-BDD4-314173B6F512Q52431661-20D1EB86-84DA-4083-9945-27B38DC2AC3EQ52431943-C692D90C-9CAC-42B2-B025-614BD531CA59Q54979175-DD806B78-684B-4E22-BC26-AC850C9A5D1AQ55128220-2135B942-0556-415A-A180-2D51753B2074Q55228025-6E8DBC63-8D6D-4035-8AB2-B88845DAF6E0Q56057560-FEFB1CB5-7E2C-453E-8DB0-E38734C8C8FCQ57061947-3B2266CB-42A6-4BA3-9F56-81EF0E9B4167Q57139324-2370FA13-C964-4EE5-BC97-89BFEA86DDD3Q57172546-C958D5D1-C896-459B-BED9-49C3CEF62FDBQ58760448-42F80FFB-55F3-4077-9057-135B49141A47
P2860
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A non-viral CRISPR/Cas9 delive ...... ing HBV DNA and pcsk9 in vivo.
@en
type
label
A non-viral CRISPR/Cas9 delive ...... ing HBV DNA and pcsk9 in vivo.
@en
prefLabel
A non-viral CRISPR/Cas9 delive ...... ing HBV DNA and pcsk9 in vivo.
@en
P2093
P2860
P356
P1433
P1476
A non-viral CRISPR/Cas9 delive ...... ting HBV DNA and pcsk9 in vivo
@en
P2093
Chao Jiang
Qiannan Wang
Wenhong Zu
Xiurui Zhu
Yizhou Dong
Yujie Tian
P2860
P2888
P304
P356
10.1038/CR.2017.16
P577
2017-01-24T00:00:00Z
P6179
1074192999